טקסוטר

Ülke: İsrail

Dil: İbranice

Kaynak: Ministry of Health

Aktif bileşen:

DOCETAXEL AS TRIHYDRATE 20 MG / 1 ML

Mevcut itibaren:

SANOFI - AVENTIS ISRAEL LTD

ATC kodu:

L01CD02

Farmasötik formu:

CONCENTRATE FOR SOLUTION FOR INFUSION

Uygulama yolu:

I.V

Tarafından üretildi:

SANOFI - AVENTIS DEUTSCHLAND GMBH, GERMANY

Terapötik grubu:

DOCETAXEL

Terapötik endikasyonlar:

Breast cancer: Taxotere (docetaxel) in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer. Taxotere (docetaxel) in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. Taxotere(docetaxel) monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent. Taxotere (docetaxel) in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress HER2 and who previously have not received chemotherapy for metastatic disease. Taxotere (docetaxel) in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy.

Yetkilendirme tarihi:

2012-11-01